Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 19/20 | 0.54 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.47 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL384873 | 1.00 | DGAT1 (0.54) | DGAT1SOAT1SOAT2FAAHCHRM2 | |
| SCHEMBL463588 | 0.86 | DGAT1 (0.44) | DGAT1SOAT1SOAT2 | |
| SCHEMBL463587 | 0.86 | DGAT1 (0.44) | DGAT1SOAT1SOAT2 | |
| SCHEMBL13190255 | 0.78 | EPHX2 (0.46) | — | |
| SCHEMBL4940938 | 0.75 | DGAT1 (0.59) | DGAT1SOAT1SOAT2FAAHCHRM2 | |
| SCHEMBL409806 | 0.74 | DGAT1 (0.55) | DGAT1SOAT1SOAT2DGAT2 | |
| SCHEMBL409807 | 0.74 | DGAT1 (0.55) | DGAT1SOAT1SOAT2DGAT2 | |
| SCHEMBL460440 | 0.73 | DGAT1 (0.48) | DGAT1SOAT1SOAT2 | |
| SCHEMBL460439 | 0.73 | DGAT1 (0.48) | DGAT1SOAT1SOAT2 | |
| SCHEMBL463281 | 0.73 | DGAT1 (0.86) | DGAT1SOAT1SOAT2DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DGAT1 2/4885SOAT1 18/4885SOAT2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.